GlassScriptPhysician profile
Robin Demi Ross
NPI 1114951506
$8,106.80
in general payments reported to CMS, 2019-2025
22 companies · $391 in 2025
The $391 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202 · 2020: $409 · 2021: $3,187 · 2022: $1,812 · 2023: $1,432 · 2024: $673 · 2025: $391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,379 · Consulting Fee: $1,100 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,378.65 |
| Consulting Fee | $1,100.00 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $4,784.99 | 2019-2023 | Tepezza |
| Regeneron Pharmaceuticals, INC. | $1,100.00 | 2023 | Eylea |
| Alimera Sciences, INC. | $473.59 | 2020-2024 | Iluvien, Yutiq |
| Bausch & Lomb Americas INC. | $224.76 | 2022-2025 | Xipere, Visudyne, Retisert |
| Oyster Point Pharma, INC. | $185.81 | 2022-2023 | Tyrvaya |
| Alcon Vision LLC | $180.68 | 2020-2025 | Hydrus Microstent, Eysuvis |
| Johnson & Johnson Surgical Vision, INC. | $176.97 | 2020-2024 | Lipiflow System Activator (Disposable) |
| Haag-Streit USA, INC. | $143.75 | 2024 | |
| Genentech USA, INC. | $128.48 | 2021-2023 | Vabysmo |
| Tearlab Corp | $122.01 | 2020 | |
| Lumibird Medical INC. | $112.92 | 2025 | |
| Biotissue Holdings INC. | $77.62 | 2021-2023 | |
| Apellis Pharmaceuticals, INC. | $77.56 | 2023-2024 | Syfovre |
| Ani Pharmaceuticals, INC. | $71.87 | 2025 | Iluvien, Yutiq |
| Carl Zeiss Meditec, INC. | $66.11 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $48.28 | 2022-2024 | Oxervate |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Abbott Laboratories | $28.76 | 2022 | |
| Astellas Pharma US INC | $25.50 | 2025 | Izervay |
| Sun Pharmaceutical Industries INC. | $20.03 | 2020 | |
| Kala Pharmaceuticals, INC. | $18.31 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.